Fibrosis drug shows promise in delaying ovarian aging

New study highlights potential treatment for extending ovarian function and improving women’s health.

A new study has identified a treatment that could delay ovarian aging and improve reproductive and overall health in women. The study, conducted on mice, shows potential for future applications in humans, specifically targeting ovarian fibrosis – a condition that leads to ovarian scarring and hormone decline as women age. Though the treatment, involving the drug Pirfenidone, is not yet ready for clinical use in women due to side effects, it opens doors to a novel approach in maintaining ovarian health as women age.

My take on this: While not widely discussed, ovarian aging is an essential issue in women’s health, as it is intricately linked to declining hormone levels that affect everything from fertility to bone density and cardiovascular health. While women now live longer than ever before, their ovaries begin to lose function well before the end of their lifespan, resulting in years or even decades of reduced quality of life. Many women enter menopause in their early 50s, but as life expectancy has increased, they often spend many years dealing with the health consequences of ovarian aging battling comorbidity and poor health. Addressing ovarian aging not only benefits fertility but is crucial to extending healthspan, ensuring women live healthier lives for longer.

In a study published in GeroScience, researchers led by Francesca Duncan, associate professor of obstetrics and gynecology at Northwestern University Feinberg School of Medicine, explored the potential of Pirfenidone – a drug commonly used to treat pulmonary fibrosis – in reversing ovarian fibrosis in mice. The study demonstrated that reducing scarring in ovaries could extend their functional lifespan, potentially keeping hormone production stable for longer and mitigating the decline in overall health that often accompanies menopause.

“We’ve changed the landscape of how we live, and our ovarian function needs to catch up so that we have an organ that functions proportionately to maintain women’s healthspans longer,” Duncan said.

The researchers’ key finding was that reducing ovarian fibrosis could improve follicle numbers, enhance ovulation and preserve hormone levels, offering a comprehensive solution to age-related ovarian decline. Duncan explained: “If you fix the ovarian environment, you solve all the problems because you have follicles and eggs that can contribute to fertility and hormone production. It’s fixing the root of the issue.”

While current fertility treatments, such as egg freezing, address only the short-term goal of preserving fertility, they do not tackle the broader issue of hormonal decline that results from aging ovaries. Egg freezing is a stopgap measure that does not address the underlying condition of ovarian aging, but the new research goes beyond this, aiming to preserve ovarian health and the production of vital hormones like estrogen and progesterone, which are crucial for maintaining bone density, heart health and cognitive function.

Discover how a new study may improve women's health and delay ovarian aging, revolutionizing reproductive care, right HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!